PMID: 16639171Apr 28, 2006Paper

Disturbances of glucose and lipid metabolism during treatment with new generation antipsychotics

Current Opinion in Psychiatry
Maria A Rettenbacher

Abstract

The purpose of this paper is to review the recent literature about alterations of lipid and glucose metabolism in patients treated with second generation antipsychotics. This article also addresses possible underlying mechanisms of these changes and discusses ways of preventing these side-effects as well as their management. There is a considerable number of reports on this issue but very few prospective controlled trials dealing with this very important subject. This review further focuses on the question of whether there is a difference with respect to such alterations between the available new generation antipsychotics, depending on their receptor profiles. As adverse metabolic effects have a high impact on the physical health of schizophrenia patients as well as on their treatment adherence, this is a topic of major clinical relevance, with implications for public health.

References

Jan 1, 1991·Life Sciences·K M Wozniak, M Linnoila
Mar 1, 1990·Diabetic Medicine : a Journal of the British Diabetic Association·M E LeanP H Garthwaite
Sep 1, 1996·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·P Ghaeli, R L Dufresne
Apr 7, 1998·Circulation·J B RuigeL M Bouter
Nov 3, 1998·Biological Psychiatry·D A WirshingW C Wirshing
Apr 8, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·D G DanielM Lakshminarayanan
Apr 15, 1999·Clinical Neuropharmacology·B SpivakA Weizman
Dec 10, 1999·The Journal of Clinical Psychiatry·D N OsserR L Dufresne
Jun 1, 2000·The American Journal of Psychiatry·D C HendersonD C Goff
Jul 21, 2000·The Journal of Clinical Investigation·G I Shulman
Feb 24, 2001·Journal of the American Academy of Child and Adolescent Psychiatry·M Nguyen, T Murphy
Jun 2, 2001·Journal of Clinical Psychopharmacology·J P LindenmayerA Kotsaftis
Jun 20, 2001·The Journal of Clinical Psychiatry·S J KingsburyG M Simpson
Jul 10, 2001·Psychiatry and Clinical Neurosciences·J IshigookaUNKNOWN Olanzapine Early-Phase II Study Group
Jul 31, 2001·Journal of Clinical Psychopharmacology·J M Meyer
Sep 20, 2001·The Journal of Clinical Psychiatry·D C HendersonD Hayden
Oct 20, 2001·Journal of Child and Adolescent Psychopharmacology·S E Domon, J C Webber
Nov 29, 2001·The Annals of Pharmacotherapy·A M AvramS Kalhan
Mar 8, 2002·European Archives of Psychiatry and Clinical Neuroscience·J WiltfangE Rüther
Apr 2, 2002·The American Journal of Psychiatry·Michael J SernyakRobert Rosenheck
Apr 3, 2002·Archives of General Psychiatry·John W NewcomerGregg Selke
Apr 3, 2002·Psychosomatics·Kristina Melkersson, Anna-Lena Hulting
May 15, 2002·Journal of Clinical Psychopharmacology·Philip S WangJerry Avorn
Jun 7, 2002·The Journal of Clinical Endocrinology and Metabolism·Margaret O SowellJamie Dananberg
Aug 3, 2002·The American Journal of Psychiatry·Scott H Yang, Marguerite J McNeely
Oct 9, 2002·European Child & Adolescent Psychiatry·A Martin, S L'Ecuyer
Oct 31, 2002·Human Psychopharmacology·Beang-Jin Chae, Byung-Jo Kang
Nov 6, 2002·The Journal of Clinical Psychiatry·Donna A WirshingWilliam C Wirshing
Nov 6, 2002·The Journal of Clinical Psychiatry·Steven C StonerCynthia D Farrar
Nov 28, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Karin HedenmalmOlav Spigset
May 21, 2003·The Journal of Clinical Psychiatry·Michael J SernyakRobert Rosenheck
Jan 20, 2004·The Journal of Clinical Psychiatry·Christoph F EbenbichlerW Wolfgang Fleischhacker
Jan 30, 2004·Diabetes Care·UNKNOWN American Diabetes AssociationUNKNOWN North American Association for the Study of Obesity
Jan 30, 2004·Recent Progress in Hormone Research·Gerald ReavenTracey McLaughlin

❮ Previous
Next ❯

Citations

Oct 19, 2006·European Journal of Pharmacology·Basanagouda M PatilBanappa S Unger
May 10, 2008·The International Journal of Neuropsychopharmacology·Consuelo Walss-BassAsish R Chaudhuri
Jul 31, 2008·The Annals of Pharmacotherapy·Ariel HammermanMargalit Goldfracht
Feb 28, 2008·Clinical Neuropharmacology·Vladimir LernerMichael S Ritsner
Jan 4, 2019·CNS Spectrums·Mao-Hsuan HuangTzeng-Ji Chen

❮ Previous
Next ❯

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here